The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.
Obamacare? Trumpcare? These stocks don't care.
Here's how to rake in the profits off some potential big breakouts.
Here are Tuesday's top research calls, including upgrades for Disney, Continental Resources and Agios Pharmaceuticals, and downgrades for Chipotle, Brinker International and JPMorgan Chase.